RecruitingNot Applicable

Non-Abstinence Outcomes in Methamphetamine Use Disorder

United States300 participantsStarted 2026-01-14

Plain-language summary

Reduced drug use is a clinically meaningful target for treatment development, but few studies have evaluated the positive impacts produced by this behavioral change, preventing adoption of this endpoint in clinical trials. The proposed research will fill that critical knowledge gap by demonstrating the biopsychosocial benefits of reduced methamphetamine use. These data will be used to change current accepted methamphetamine treatment endpoints and accelerate identification of therapies for methamphetamine use disorder.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * be age 18 years or older; * self-report methamphetamine use in the week prior to screening; * provide a methamphetamine-positive urine sample at screening; * meet DSM-5 criteria for moderate-severe Methamphetamine Use Disorder (MUD); * be seeking treatment for their methamphetamine use * be able and willing to commit to the 12-week intervention, as well as the 12-week post-intervention follow-up * Individuals who meet these criteria and are stably maintained on buprenorphine or methadone for Opioid Use Disorder (OUD) will also be eligible to participate. Exclusion Criteria: * current or past medical or psychiatric illness (e.g., physical dependence on any drug other than buprenorphine requiring medically managed detoxification, unstable angina, uncontrolled cardiac arrhythmia, aortic stenosis, self-reported compromised immune function, severe diagnosis for a SUD other than MUD or treated OUD) that would interfere with study participation in the opinion of the study physicians * poor venous access precluding blood draws

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Mean Arterial Pressure

Timeframe: At baseline.

Mean Arterial Pressure

Timeframe: Week 1 of participation.

Mean Arterial Pressure

Timeframe: Week 2 of participation.

Mean Arterial Pressure

Timeframe: Week 3 of participation.

Mean Arterial Pressure

Timeframe: Week 4 of participation.

Mean Arterial Pressure

Timeframe: Week 5 of participation.

Mean Arterial Pressure

Timeframe: Week 6 of participation.

Mean Arterial Pressure

Timeframe: Week 7 of participation.

Trial details

NCT IDNCT07226596

SponsorWilliam Stoops

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2031-01-04

Contact for this trial

William W Stoops, PhD

8592575388 william.stoops@uky.edu

View on ClinicalTrials.gov More Methamphetamine Use Disorder trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Mean Arterial Pressure

Timeframe: At baseline.

Mean Arterial Pressure

Timeframe: Week 1 of participation.

Mean Arterial Pressure

Timeframe: Week 2 of participation.

Mean Arterial Pressure

Timeframe: Week 3 of participation.

Mean Arterial Pressure

Timeframe: Week 4 of participation.

Mean Arterial Pressure

Timeframe: Week 5 of participation.

Mean Arterial Pressure

Timeframe: Week 6 of participation.

Mean Arterial Pressure

Timeframe: Week 7 of participation.